Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD)

NCT03806478 is registered in ClinicalTrials.gov with Aphios as lead sponsor.

NCT NCT03806478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03806478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD)
Lead sponsor
Aphios
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2023
Completion date
December 31, 2024
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease 1, alzheimer disease 2, alzheimer disease 3, dementia